Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Fulvestrant plus vandetanib versus placebo for the treatment of patients with metastatic breast cancer resistant to aromatase inhibitor therapy (FURVA): a multicentre, Phase 2, randomised controlled trial.
Beresford M, Casbard A, Hudson Z, Carucci M, Ingarfield K, Gee J, Smith J, Kitson T, Alchami F, Madden TA, Hayward L, Hwang D, Spensley S, Waters S, Wheatley D, Jones RH. Beresford M, et al. Among authors: casbard a. BJC Rep. 2023 Sep 14;1(1):13. doi: 10.1038/s44276-023-00016-8. BJC Rep. 2023. PMID: 39516358 Free PMC article.
Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trial.
Murphy AD, Porter C, White A, Irving A, Adams R, Ray R, Casbard A, Mahmood RD, Karanth S, Zhou C, Pugh J, Wheeler C, Roberts V, Arnetoli G, Salih Z, Hasan J, Mitchell C, Morgan RD, Clamp AR, Jayson GC. Murphy AD, et al. Among authors: casbard a. Int J Gynecol Cancer. 2024 Jul 1;34(7):1034-1040. doi: 10.1136/ijgc-2024-005455. Int J Gynecol Cancer. 2024. PMID: 38724236 Clinical Trial.
Remotely Delivered Video Interaction Guidance for Families of Children With an Intellectual Disability Referred to Specialist Mental Health Services: Protocol for a Feasibility Randomized Controlled Trial.
Kohn C, Turner L, Yang Z, Absoud M, Casbard A, Gomes M, Grant G, Hassiotis A, Kennedy E, Levitt S, McNamara R, Randell E, Totsika V. Kohn C, et al. Among authors: casbard a. JMIR Res Protoc. 2024 Dec 5;13:e54619. doi: 10.2196/54619. JMIR Res Protoc. 2024. PMID: 39636678 Free PMC article.
Watch Me Play!: protocol for a feasibility study of a remotely delivered intervention to promote mental health resilience for children (ages 0-8) across UK early years and children's services.
Randell E, Nollett C, Henley J, Smallman K, Johnson S, Meister L, McNamara R, Wilkins D, Segrott J, Casbard A, Wakelyn J, McKay K, Bordea E, Totsika V, Kennedy E. Randell E, et al. Among authors: casbard a. Pilot Feasibility Stud. 2024 Apr 4;10(1):55. doi: 10.1186/s40814-024-01491-7. Pilot Feasibility Stud. 2024. PMID: 38576026 Free PMC article.
Mapping the pathway and support offered to children with an intellectual disability referred to specialist mental health services in the UK.
Totsika V, Yang Z, Turner L, Kohn C, Hassiotis A, Kennedy E, Absoud M, McNamara R, Randell E, Levitt S, Grant G, Casbard A, Jacobs L, Di Santo C, Buckley C, Hignett E, Liew A. Totsika V, et al. Among authors: casbard a. BJPsych Bull. 2024 Oct 8:1-6. doi: 10.1192/bjb.2024.63. Online ahead of print. BJPsych Bull. 2024. PMID: 39376126 Free article.
Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial.
Fennell DA, Porter C, Lester J, Danson S, Blackhall F, Nicolson M, Nixon L, Gardner G, White A, Griffiths G, Casbard A. Fennell DA, et al. Among authors: casbard a. EClinicalMedicine. 2022 Aug 11;52:101595. doi: 10.1016/j.eclinm.2022.101595. eCollection 2022 Oct. EClinicalMedicine. 2022. PMID: 35990583 Free PMC article.
Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial.
Fennell DA, Porter C, Lester J, Danson S, Taylor P, Sheaff M, Rudd RM, Gaba A, Busacca S, Nixon L, Gardner G, Darlison L, Poile C, Richards C, Jordan PW, Griffiths G, Casbard A. Fennell DA, et al. Among authors: casbard a. EClinicalMedicine. 2022 May 19;48:101432. doi: 10.1016/j.eclinm.2022.101432. eCollection 2022 Jun. EClinicalMedicine. 2022. PMID: 35706488 Free PMC article.
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial.
Howell SJ, Casbard A, Carucci M, Ingarfield K, Butler R, Morgan S, Meissner M, Bale C, Bezecny P, Moon S, Twelves C, Venkitaraman R, Waters S, de Bruin EC, Schiavon G, Foxley A, Jones RH. Howell SJ, et al. Among authors: casbard a. Lancet Oncol. 2022 Jul;23(7):851-864. doi: 10.1016/S1470-2045(22)00284-4. Epub 2022 Jun 4. Lancet Oncol. 2022. PMID: 35671774 Free PMC article. Clinical Trial.
42 results